Inhibrx Biosciences, Inc. 4

Insider Jon Faiz Kayyem indirectly purchased 5,000 shares of Inhibrx Biosciences, Inc. common stock at about $113.52 per share, totaling roughly $567.6K, via a family trust.

On September 8, 2026, reporting person Jon Faiz Kayyem, through The Jon F. Kayyem and Paige Gates-Kayyem Family Trust, purchased 5,000 shares of Inhibrx Biosciences, Inc. common stock at a weighted-average price of $113.516 per share, for an approximate total of $567,580. The transaction was executed in multiple trades within a price range of $113.30 to $113.55, with the reported price representing the volume-weighted average. Following the purchase, indirect holdings by the Family Trust increased to 424,360 shares, while additional indirect holdings are maintained via the Jon Faiz Kayyem Revocable Trust (250,000 shares), the Paige Gates-Kayyem Revocable Trust (250,000 shares), and custodial accounts for two minor children (69,843 shares each). Kayyem disclaims beneficial ownership of certain of these indirect holdings except to the extent of any indirect pecuniary interest, but in aggregate the filing reflects a sizable insider purchase that increases his overall economic exposure to the issuer.

Filing Facts

CIK

2007919

Ticker

INBX

Form

4

Source Type

fda

Accession

0001366268-26-000004

Alert Tier

7